BCL2 and Thrombocytopenia: Its superior efficacy, along with fewer side effects—attributable to selective BCL2 inhibition without inducing thrombocytopenia or damaging healthy tissue (Fig. 3K, P and I, N)—support its preference over Navitoclax for AP therapy.